Under reduced chamber pressure during lyophilisation, bromobutyl rubber closures are seated only partially in the upward vented position to allow water vapour migration from the freezing chamber toward the condenser. The stopper compound must simultaneously satisfy the extractable profile of USP <381>, the functional suitability requirements of USP <382>, and the physicochemical constraints of Ph. Eur. 3.2.9. Halogenated butyl rubber is selected for this duty because its olefin backbone provides a low gas transmission path that resists oxygen ingress after final stoppering while retaining sufficient elasticity to reseal after needle penetration. Preparation of stoppers for lyophilised injectables starts with washing in water for injection at 80°C to 90°C followed by target siliconization in the range of 0.25 mg/cm² to 0.75 mg/cm² of polydimethylsiloxane, a level that prevents sticking during automatic feeding without producing excessive free silicone that would later deposit on the freeze-dried cake. Following silicone treatment, stoppers are dried until residual moisture is reduced to ≤0.5 wt%, a limit that is critical because residual water in the elastomer can transfer into the lyophilisation chamber and extend secondary drying time or elevate final product moisture. Lyophilisation cycles for injectable APIs are developed around formulation-specific collapse temperatures, with product temperature during primary drying normally controlled at 2°C to 5°C below the collapse temperature and chamber pressure held in the 13 Pa to 20 Pa range. After primary drying, the shelf temperature is raised stepwise for secondary drying to reduce product moisture to a monograph-defined limit, often below 1.0 wt% for freeze-dried powders intended for reconstitution. When the stopper is pressed into the vial neck under vacuum or nitrogen at the end of the cycle, the residual moisture of the elastomer and the compression set behaviour of the compound directly affect closure integrity during storage, distribution, and reconstitution. The resulting finished product is a freeze-dried injectable powder sealed under a butyl closure that must meet sterility testing per USP <71> and bacterial endotoxin limits per USP <85>, with stopper penetration force and fragmentation characteristics verified by ISO 8871-5:2016 before batch release.

How Does Terminal Steam Sterilisation of Aqueous Large-Volume Parenterals Alter Closure Compression Set Requirements?

Aqueous large-volume parenterals sealed with chlorobutyl or bromobutyl rubber closures are exposed to moist-heat sterilisation cycles that impose a different stress profile from lyophilisation. The stopper is placed onto the filled bottle or infusion container before the complete closure system is loaded into a steam autoclave and heated at 121.1°C for a validated cycle that commonly delivers a minimum F0 value of 12 min. Under these conditions the elastomer undergoes hydrothermal ageing: crosslink density increases, low-molecular-weight oligomers may migrate, and compression set performance becomes the controlling property for maintaining closure integrity after the container cools. Compounds based on halogenated butyl elastomer are formulated with sulfur-free or resin-cure systems to limit extractables and to retain low compression set after repeated steam exposure. Compression set testing is performed according to ISO 815-1:2019, with typical acceptance values for injectable closure compounds remaining below 25% after 70 h at 70°C. Terminal sterilisation also requires the stopper to tolerate headspace expansion without gas blow-back or delamination of the aluminium crimp cap. The functional suitability of the elastomer after autoclaving is confirmed by penetration, reseal, and fragmentation tests according to USP <382> and ISO 8871-5:2016. Aqueous extractable testing per USP <381> is conducted on closures that have been autoclaved once, and in some registration strategies after multiple autoclave cycles, to verify that pH shift, reducing substances, turbidity, and UV absorbance remain within monograph limits. The finished container may be a 100 mL, 250 mL, 500 mL, or 1000 mL glass bottle for infusion, sealed with a 28 mm or 32 mm butyl closure and aluminium tear-off cap. The stopper compound is selected not only for extractable profile but also for insertion-line behaviour because high-speed stoppering of large-volume bottles requires consistent Shore A hardness, typically in the 45 to 55 range, to avoid jamming in vibratory bowl feeders and to ensure uniform seating on the bottle lip before crimping.

Dry-Powder Injectable Packaging and Elastomer Moisture Ingress Control

Dry-powder injectable products, including beta-lactam antibiotics in glass vials, place the elastomer closure in direct contact with a moisture-sensitive active pharmaceutical ingredient that may hydrolyse rapidly if water vapour penetrates the seal. Chlorobutyl and bromobutyl compounds are preferred over natural rubber and many synthetic polyisoprene grades because their halogenated isobutylene structure reduces moisture and oxygen permeation through the closure into the vial headspace. The stopper supplier is normally required to control residual moisture to ≤0.5 wt% after washing and drying, with some products specifying pre-drying at 80°C to 105°C for 2 h to 4 h before loading into the filling line. In dry-powder filling, the vial is filled with sterile API powder, the stopper is seated immediately, and an aluminium crimp cap is applied under controlled room humidity. Closure break-loose and residual seal force testing are performed on the capped vial to verify that the stopper has not been deformed during high-speed capping. The applicable container closure standards for this dosage form are ISO 8362-2:2015 for vial closures and ISO 8871-2:2003 for chemical extractables after steam processing. In addition, 21 CFR 211.94 requires the container closure system to provide adequate protection against moisture, oxygen, and contamination for the labelled shelf life. The table below summarises the compliance matrix that applies to stopper compounds used in dry-powder injectable packaging.

For highly hygroscopic dry powders, the stopper insert is often supplied in low-shedding packaging with desiccant protection, and the manufacturer may apply a vacuum or nitrogen flush before final stoppering. The selection between chlorobutyl and bromobutyl is governed by cure rate, metal oxide content, and extractable profile: bromobutyl grades generally permit faster cure with lower zinc oxide levels, but chlorobutyl grades can offer lower permeability and broader industrial availability. The finished product is a dry-powder vial that must meet sterility, endotoxin, and particulate matter requirements before release.

For direct compression of high-dose tablet APIs, the active pharmaceutical ingredient is blended with microcrystalline cellulose, partially pregelatinised starch, croscarmellose sodium, and magnesium stearate before compaction on a rotary tablet press. The API must possess sufficient flow and compressibility to produce tablets with consistent weight and acceptable hardness at press speeds typical of commercial manufacturing. Powder flow is evaluated according to USP <1174>, with direct compression candidates generally requiring a Carr index below 20% or a measured angle of repose below 35°. Particle size distribution is controlled because excessive fines can cause segregation in the hopper, while coarse particles can produce capping and lamination at the compression stage. A pharma-grade API used for direct compression is commonly milled to a D90 below 250 µm and a D50 in the 50 µm to 150 µm range. The lubricant level is kept low, usually 0.5 wt% to 1.0 wt% magnesium stearate, and blending is limited to 3 min to 5 min after all other excipients have been mixed, because over-lubrication can reduce tablet breaking force and slow dissolution. Tablet hardness, friability, disintegration, and dissolution are tested according to USP <1217>, USP <701>, USP <711>, and the individual drug product monograph. The finished oral dosage form is a tablet or hard capsule filled with the compressed blend or with granules derived from it. When the API dose is low, direct compression may require a pre-blend with a diluent to improve content uniformity as measured by USP <905>. For APIs with moisture sensitivity, dry granulation is preferred over wet granulation to avoid hydrolysis during processing.

When High-Dose Granule APIs Require Roller Compaction Instead of Wet Granulation

If a high-dose API is moisture-sensitive or thermolabile, wet granulation in a high-shear mixer followed by fluid-bed drying may produce unacceptable degradation products or form hard granules that require excessive compaction force. In this case, dry granulation by roller compaction is used to densify the API-containing blend into ribbons, which are then milled through a screen to form free-flowing granules for tablet compression or capsule filling. The roller compactor is operated with roll pressure typically in the range of 4 MPa to 12 MPa, roll gap between 2 mm and 5 mm, and screen aperture between 0.8 mm and 1.6 mm. The resulting granules are characterised for tapped bulk density, angle of repose, and sieve fraction before charging to the tablet press or capsule filling machine. Granule size distribution is important for good flow into the die and for consistent fill weight. A common target is a granule D50 between 150 µm and 300 µm with a fines fraction below 20% through a 125 µm sieve, although individual formulations vary. Tablet compression of dry granules is performed on a rotary press with precompression force controlled to avoid lamination, while capsule filling on a dosing-disc or dosator-type machine requires granule uniformity and low dust generation. The table below contrasts granulation routes for pharma-grade APIs used in oral solid dosage forms.

After compression, the tablets are coated when required and tested for hardness, friability, disintegration, dissolution, and assay. The granule intermediate may also be filled into hard gelatin or hydroxypropyl methylcellulose capsules. The final product specification for the API must align with the applicable pharmacopoeial monograph and with ICH impurity requirements, including organic impurities under ICH Q3A, residual solvents under ICH Q3C, and elemental impurities under ICH Q3D.

When injectable-grade API solutions are filled into pre-sterilised glass vials, the process train must reduce microbial burden, endotoxin, and particulate load before the final sterile filtration step. The API is dissolved in water for injection, pH-adjusted with hydrochloric acid or sodium hydroxide solution, and filtered through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane. The filtrate is filled under aseptic isolator or restricted access barrier system conditions into depyrogenated Type I glass vials, and bromobutyl or chlorobutyl stoppers that have been washed, siliconized, and steam-sterilised are seated and crimped. The stopper compound must comply with USP <381> and Ph. Eur. 3.2.9 for the relevant aqueous injectable application, while the filled solution must meet USP <788> particulate matter limits by light obscuration. Sterility is verified by USP <71> and endotoxin by USP <85>, with the latter limit established on a product-specific basis from the maximum permissible endotoxin exposure. For injectable APIs that cannot be terminally sterilised due to thermal degradation, the aseptic filling line is operated with continuous environmental monitoring of airborne viable and non-viable particulates, and the closure is often pre-treated with a target silicone level below 1.0 mg/cm² to avoid visible silicone droplets in the injectable solution. The final product is a liquid injectable solution or suspension sealed with a butyl rubber stopper and aluminium cap. For APIs that undergo terminal sterilisation in the final container, the stopper must demonstrate acceptable autoclave extractables and stable penetrability after moist-heat exposure.

Blood Collection Tube Closure Performance Is Governed by Vacuum Retention and Needle Reseal Forces

In evacuated blood collection tubes, butyl rubber stoppers perform a dual role: they maintain the internal vacuum that draws a predetermined blood volume, and they reseal after multiple needle penetrations without releasing fragments into the specimen. Halogenated butyl compounds are used because their low gas permeability limits vacuum loss during shelf life and because their elastic recovery after puncture reduces the risk of leakage during transport and centrifuge operations. The stopper is assembled into the tube under vacuum, and closure performance is checked by draw-volume testing and vacuum retention studies according to ISO 6710:2017. The compound formulation is adjusted to a Shore A hardness that balances insertion force, needle penetration, and reseal integrity, commonly in the 45 to 55 range. Needle penetration force and fragmentation are evaluated by methods adapted from ISO 8871-5:2016, while stopper extractables are controlled to avoid interference with clinical chemistry analytes. The inner surface of the tube may be coated with spray-dried anticoagulants such as dipotassium edetate or sodium citrate, and the stopper must remain inert toward these additives for the shelf life of the device. The final end product is a single-use blood collection tube with an evacuated interior and a colour-coded butyl closure that permits direct filling through a patient collection needle. The same sealing principles apply to diagnostic reagent vials and sample archiving tubes where repeated needling and low gas ingress are required over long storage intervals.